Skip to content
Clinical Trials – home

Moxifloxacin: A Comprehensive Guide for Patients

17 / 18
trials open to patients / all trials
18+
Countries

In short

This article examines the use of moxifloxacin, a broad-spectrum antibiotic, in various clinical trials. These studies investigate moxifloxacin's effectiveness, safety profile, and pharmacokinetics in different formulations and patient populations, including children and those with eye conditions. The research aims to optimize dosing strategies and evaluate potential applications of moxifloxacin in treating infections and ocular disorders.

At a glance

Drug Formulations
Oral tablets, intravenous infusions, eye drops (Vigamox)
Patient Populations
Adults, children (3 months to 14 years), patients with eye conditions
Key Study Objectives
Pharmacokinetics, safety, efficacy in various conditions
Main Pharmacokinetic Measures
AUC, Cmax, tmax, half-life, clearance, volume of distribution
Safety Assessments
Joint examinations (pediatric), ocular health, general tolerability
Ocular Applications
Bacterial conjunctivitis, ocular graft-versus-host disease
Comparison Studies
Placebo-controlled, different dosing regimens
Outcome Measures
Bacterial cultures, symptom relief, visual acuity, ocular surface health

What is Moxifloxacin?

Moxifloxacin is a powerful antibiotic medication that belongs to a class of drugs called fluoroquinolones. It is known by various brand names, including Avelox, Vigamox, and BAY12-8039. This medication works by killing bacteria or preventing their growth, making it effective against a wide range of infections.

Uses of Moxifloxacin

Moxifloxacin is used to treat various bacterial infections in different parts of the body. Some of its common uses include:

  • Periodontal (gum) infections: It can be used as a treatment for chronic periodontitis, a severe gum infection that can damage the soft tissue and bone that support your teeth.
  • Eye infections: Moxifloxacin is effective in treating bacterial conjunctivitis, also known as pink eye. It's also used to prevent endophthalmitis, a serious eye infection that can occur after eye injuries or surgeries.
  • Respiratory infections: While not explicitly mentioned in the provided trials, moxifloxacin is known to be effective against various respiratory tract infections.
  • Other bacterial infections: The drug has shown effectiveness against a wide range of bacteria, including those that are resistant to other antibiotics.

Administration Methods

Moxifloxacin can be administered in several ways, depending on the type and location of the infection:

  • Oral tablets: For systemic infections, moxifloxacin is often given as oral tablets.
  • Intravenous (IV) infusion: In some cases, especially for more severe infections or in hospital settings, moxifloxacin can be given as an IV infusion directly into the bloodstream.
  • Eye drops: For eye infections like bacterial conjunctivitis, moxifloxacin is available as an eye drop solution (e.g., Vigamox).
  • Topical gel: For periodontal infections, moxifloxacin can be applied directly to the gums as an in situ gel.

Effectiveness

Moxifloxacin has shown high effectiveness against various bacterial infections:

  • Periodontal infections: When used as an adjunct to scaling and root planing (a deep cleaning procedure for teeth), moxifloxacin has shown superior outcomes compared to other treatments.
  • Eye infections: Moxifloxacin eye drops have been effective in treating bacterial conjunctivitis and preventing post-surgical eye infections.
  • Wide spectrum of activity: Moxifloxacin is effective against many types of bacteria, including some that are resistant to other antibiotics.

Safety and Side Effects

While moxifloxacin is generally considered safe when used as directed, it can cause side effects and requires careful monitoring:

  • Blood glucose effects: Some studies have investigated the potential effects of moxifloxacin on blood glucose levels. While the results are not conclusive, patients with diabetes should be monitored closely when using this medication.
  • ECG changes: Moxifloxacin can potentially affect heart rhythm, which is why ECG (electrocardiogram) monitoring is sometimes recommended during treatment.
  • Joint-related side effects: In some cases, fluoroquinolones like moxifloxacin have been associated with joint-related side effects. This is particularly important in pediatric patients.
  • Other side effects: As with any medication, moxifloxacin can cause various side effects. Always discuss potential side effects with your healthcare provider.

Special Considerations

There are some special considerations to keep in mind when using moxifloxacin:

  • Pediatric use: The use of moxifloxacin in children is being studied to determine appropriate dosing and safety. It's important to note that fluoroquinolones are generally used cautiously in children due to potential effects on developing joints.
  • Antibiotic resistance: Like all antibiotics, the overuse or misuse of moxifloxacin can lead to antibiotic resistance. It's crucial to use this medication only as prescribed by your healthcare provider.
  • Pregnancy and breastfeeding: The safety of moxifloxacin during pregnancy and breastfeeding should be discussed with a healthcare provider.

Remember, moxifloxacin is a prescription medication and should only be used under the guidance of a healthcare professional. Always follow your doctor's instructions and complete the full course of treatment, even if you start feeling better before it's finished.

Questions people often ask

Conditions where Moxifloxacin is being studied

Each condition opens its own overview and trial list

Trials with Moxifloxacin

Recruiting trials first

See all 18 →
Quick filters
  • Participants:Adults
  • Participants:Adults
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).